文献速递乳腺外科

瑞典48 986例乳腺癌患者保乳与全乳切除生存比较:校正合并症及社会经济地位

Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status: A Swedish National 6-Year Follow-up of 48 986 Women.
PubMed 文献 · JAMA Surg · 2021-01-01

基于瑞典国家乳腺癌质量登记等全国前瞻性数据,纳入2008至2017年48 986例原发浸润性T1-2 N0-2期乳腺癌手术患者,比较保乳加放疗、全乳切除不加放疗及全乳切除加放疗三组的总体生存和乳腺癌特异生存。逐步校正合并症及社会经济地位等混杂因素后,保乳加放疗组生存仍显著优于两组全乳切除。

要点

  • 保乳加放疗组5年总生存91.1%、乳腺癌特异生存96.3%。
  • 校正合并症及社会经济地位后,保乳加放疗生存仍优于全乳切除。
  • 若两种术式均为有效选择,不应将全乳切除等同于保乳治疗。

核心结论

  • 校正合并症和社会经济地位等混杂因素后,保乳加放疗的总体生存和乳腺癌特异生存仍优于全乳切除(无论是否放疗)。
  • 若保乳与全乳切除均为有效选项,全乳切除不应被视为与保乳等同。

研究设计与样本

  • 瑞典全国性队列研究,采用前瞻性收集的国家登记数据。
  • 纳入2008至2017年瑞典所有原发浸润性T1-2 N0-2期乳腺癌并接受手术的女性,共48 986例。
  • 暴露分为保乳加放疗(29 367例,59.9%)、全乳切除不加放疗(12 413例,25.3%)和全乳切除加放疗(7 206例,14.7%)三组。
  • 主要结局为总体生存和乳腺癌特异生存,中位随访6.28年(范围0.01-11.70)。

主要发现

  • 随访期间全因死亡6 573例,乳腺癌死亡2 313例。
  • 5年总体生存率为91.1%(95% CI,90.8-91.3),乳腺癌特异生存率为96.3%(95% CI,96.1-96.4)。
  • 全乳切除不加放疗组较保乳加放疗组总体生存更差(HR,1.79;95% CI,1.66-1.92),乳腺癌特异生存更差(HR,1.66;95% CI,1.45-1.90)。
  • 全乳切除加放疗组较保乳加放疗组总体生存更差(HR,1.24;95% CI,1.13-1.37),乳腺癌特异生存更差(HR,1.26;95% CI,1.08-1.46)。

临床怎么用

  • 在临床决策中,对于保乳加放疗与全乳切除均为有效选项的早期乳腺癌患者,应告知全乳切除生存不优于保乳加放疗。
  • 评估术式选择时需考虑合并症和社会经济地位等混杂因素对生存的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cohort studies show better survival after breast-conserving surgery (BCS) with postoperative radiotherapy (RT) than after mastectomy (Mx) without RT. It remains unclear whether this is an independent effect or a consequence of selection bias. OBJECTIVE: To determine whether the reported survival benefit of breast conservation is eliminated by adjustment for 2 pivotal confounders, comorbidity and socioeconomic status. DESIGN, SETTING, AND PARTICIPANTS: Cohort study using prospectively collected national data. Swedish public health care; nationwide clinical data from the National Breast Cancer Quality Register, comorbidity data from Patient Registers at the National Board of Health and Welfare, and individual-level education and income data from Statistics Sweden. The cohort included all women diagnosed as having primary invasive T1-2 N0-2 breast cancer and undergoing breast surgery in Sweden from 2008 to 2017. Data were analyzed between August 19, 2020, and November 12, 2020. EXPOSURES: Locoregional treatment comparing 3 groups: breast-conserving surgery with radiotherapy (BCS+RT), mastectomy without radiotherapy (Mx-RT), and mastectomy with radiotherapy (Mx+RT). MAIN OUTCOMES AND MEASURES: Overall survival (OS) and breast cancer-specific survival (BCSS). Main outcomes were determined before initiation of data retrieval. RESULTS: Among 48 986 women, 29 367 (59.9%) had BCS+RT, 12413 (25.3%) had Mx-RT, and 7206 (14.7%) had Mx+RT. Median follow-up was 6.28 years (range, 0.01-11.70). All-cause death occurred in 6573 cases, with death caused by breast cancer in 2313 cases; 5-year OS was 91.1% (95% CI, 90.8-91.3) and BCSS was 96.3% (95% CI, 96.1-96.4). Apart from expected differences in clinical parameters, women receiving Mx-RT were older, had a lower level of education, and lower income. Both Mx groups had a higher comorbidity burden irrespective of RT. After stepwise adjustment for all covariates, OS and BCSS were significantly worse after Mx-RT (hazard ratio [HR], 1.79; 95% CI, 1.66-1.92 and HR, 1.66; 95% CI, 1.45-1.90, respectively) and Mx+RT (HR, 1.24; 95% CI, 1.13-1.37 and HR, 1.26; 95% CI, 1.08-1.46, respectively) than after BCS+RT. CONCLUSIONS AND RELEVANCE: Despite adjustment for previously unmeasured confounders, BCS+RT yielded better survival than Mx irrespective of RT. If both interventions are valid options, mastectomy should not be regarded as equal to breast conservation.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. de Boniface J, Szulkin R, Johansson ALV, et al. Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status: A Swedish National 6-Year Follow-up of 48 986 Women. JAMA Surg. 2021. PMID: 33950173. doi:10.1001/jamasurg.2021.1438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。